Cardiovascular Outcomes of PCSK9 Inhibitors: With Special Emphasis on Its Effect beyond LDL-Cholesterol Lowering

PCSK9 inhibitors, monoclonal antibodies, are novel antihypercholesterolemic drugs. FDA first approved them in July 2015. PCSK9 protein (692-amino acids) was discovered in 2003. It plays a major role in LDL receptor degradation and is a prominent modulator in low-density lipoprotein cholesterol (LDL-...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:J Lipids
Main Authors: Bandyopadhyay, Dhrubajyoti, Ashish, Kumar, Hajra, Adrija, Qureshi, Arshna, Ghosh, Raktim K.
Format: Artigo
Jezik:Inglês
Izdano: Hindawi 2018
Teme:
Review Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC5889852/
https://ncbi.nlm.nih.gov/pubmed/29770231
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2018/3179201
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki